Arrowhead Research | ARWR - Assets


Arrowhead Research reported $1.74B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 1.74B 373.76M Sep/2026
Heron Therapeutics USD 230.45M 21.81M Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Ligand Pharmaceuticals USD 2.24B 51.59M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Moderna USD 13.47B 2.51B Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novartis USD 117.15B 4.88B Sep/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
TG Therapeutics USD 1.59B 47.38M Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026
Xencor USD 770.5M 45.54M Sep/2026